Bowen Acquisition Corp

At this point the trust held $75.5 million and the shares traded within a cent of trust value, a normal and healthy relationship. Within four months the trust would fall to $9.36 million as holders redeemed en masse, and the shares would trade at $7.40 against $11.03 of trust value - a collapse in confidence in the PRC transaction. This proxy captures the last moment before that unwind.

Both the vote date and the registered ceiling were already fixed at this amendment: 10:00 a.m. ET on January 13, 2025, and 8,646,377 ordinary shares. The webcast address is published, so the meeting is fully specified. The operating business is PRC-incorporated and held beneath a newly formed Cayman holding company.

The registered ceiling of 8,646,377 ordinary shares is already fixed at this amendment and holds unchanged through the later versions of this registration statement. The meeting, by contrast, is entirely unspecified — date, time and even the final segment of the webcast URL are placeholders — so this version establishes no vote date and no redemption deadline. Note that the webcast host path here ('bowenacquisition') differs from the one published in the later amendments of this registration statement, so a URL taken from this version would not be the operative one.

The 8,646,377-share ceiling is fixed; the meeting is not. No date, time or complete access URL appears, so this version sets no deadline. The webcast host path differs from the address published in the later amendments of this registration statement, so it should not be relied on.

The 8,646,377-share registered ceiling is already set at this first amendment and does not change through the rest of this registration statement's amendments. Nothing about the meeting is fixed — no date, no time, no complete URL — so no deadline follows from this version.

This is the baseline of the Bowen / Qianzhi registration and it already fixes the registered ceiling at 8,646,377 ordinary shares — a figure that does not move through any later amendment of this registration statement. Nothing about the meeting is fixed. The operating target is PRC-incorporated and sits beneath a newly formed Cayman holding company, so the listed entity will hold operations subject to PRC jurisdiction through an offshore structure.

What changed: Bowen Acquisition Corp, a Cayman Islands exempted company, filed a preliminary proxy for an extraordinary general meeting on June 11, 2026 at 10:00 a.m. Eastern Time, held virtually. The sole substantive proposal is an Extension Amendment, by special resolution, to its memorandum and articles of association — adopted July 13, 2023 and further amended April 14, 2025 — allowing the board to extend the date by which it must consummate a business combination from June 14, 2026, the Current Termination Date, to as late as December 31, 2026. Adjournment is the second proposal. Why it matters: June 14, 2026 is the date that BINDS; December 31, 2026 is the ceiling the vote would create, and the amendment leaves the board discretion to set any earlier date. Bowen is not searching: shareholders approved its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. in January 2025 and it has been seeking to consummate that transaction since. The company says it may abandon the Extension Proposal at any time, including if it closes with Qianzhi on or before June 14, 2026. Without the extension it would be required to cease operations, liquidate and dissolve.

What changed: Bowen Acquisition Corp called an extraordinary general meeting for 10:00 a.m. Eastern Time on December 12, 2025, held virtually, to approve an Extension past the Current Termination Date of December 14, 2025. Bowen has a definitive agreement for its initial business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. Based on the trust balance of approximately $8.26 million as of November 20, 2025, the anticipated redemption price is approximately $11.35 per public share. Why it matters: The trust floor is roughly $11.35 a share on $8.26 million, and redemption is available at the meeting whether or not the extension passes - so the downside is cash, not zero. The risk is qualitative: the target is a PRC-incorporated company, which brings regulatory and audit-access complications that have delayed or killed comparable deals. Holders who stay in accept that risk for the chance at deal upside above trust.